Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

FDA lifts clinical hold on Alnylam Pharmaceuticals' fitusiran

Dec. 18, 2017

First in vivo results for LSD1 inhibitor show promise for the treatment of SCD

Dec. 15, 2017

Vertex enters development agreement with CRISPR Therapeutics for gene-editing treatment

Dec. 14, 2017

Positive first-in-human data for new complement C3 inhibitor AMY-10

Dec. 14, 2017

Principia Biopharma begins clinical studies of PRN-1008 in ITP

Dec. 14, 2017

EMA's CHMP requests additional information for betrixaban MAA

Dec. 13, 2017

Rockefeller University presents novel FXIIa inhibitors

Dec. 12, 2017

CRISPR Therapeutics applies to conduct clinical trial of CTX-001

Dec. 12, 2017

Janssen submits sNDA in U.S. for two new Xarelto indications

Dec. 12, 2017

OG-L002 shows promising in vivo results for the treatment of sickle cell disease

Dec. 11, 2017

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...